Vivera Pharmaceuticals, a US-based pharmaceutical company, announced on Thursday that it has added Fabio Macciardi, MD, PhD to its Advisory Board as neurogenetics scientific advisor to the company's Biosciences Division.
In this role, Dr. Macciardi is to assist the company in the research and development of targeted genetic therapies to address the unmet requirements of patients with various central nervous system (CNS) conditions.
Dr. Macciardi is a Professor of Molecular Psychiatry at the University of California, Irvine (UCI) School of Medicine. He is currently leading research focused on evaluating the function and evolution of neurocognitive genes and their associated traits using next-generation DNA and RNA sequencing methods.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference